Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.0700-0.0300 (-0.97%)
At close: 04:00PM EDT
3.0600 -0.01 (-0.33%)
After hours: 04:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close3.1000
Open3.0000
Bid2.9900 x 2200
Ask3.1600 x 1400
Day's Range2.9850 - 3.1450
52 Week Range1.3100 - 6.3300
Volume784,968
Avg. Volume1,722,006
Market Cap579.389M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LXRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Lexicon Pharmaceuticals, Inc.
    The Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Simply Wall St.

    Do Institutions Own Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares?

    The big shareholder groups in Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) have power over the company. Institutions...

  • InvestorPlace

    7 Biotech Stocks With Key Catalysts for May

    Biotech stocks have been through an extended lean patch, making them ideal candidates for a strong rebound. Verrica (VRCA): Approval of its viral skin disease treatment could transform the company into a commercial-stage biopharma. Amicus (FOLD): Pompe disease treatment approval opens up huge market opportunity for the biopharma. Athersys (ATHX): Potential approval for Japanese licensee would provide additional financing options. Nanobiotix (NBTX): Stock could be in for a reversal if ASCO abstra

  • Benzinga

    Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin Commercialization

    Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) entered into a loan facility with Oxford Finance LLC for 0 million to support commercial preparations and the potential launch of sotagliflozin in heart failure. The loan facility consists of four tranches, each maturing in March 2027. An initial $25 million tranche was funded at closing. The second $25 million tranche is available before August 31, contingent upon the acceptance of filing by the FDA of Lexicon's planned resubmission of sotagliflozin fo

Advertisement
Advertisement